Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
The approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO
Effectiveness of Covaxin against the Omicron variant is currently being studied
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
It’s a two-dose vaccine administered 28 days apart
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
Subscribe To Our Newsletter & Stay Updated
